SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial

Study limitation reported by the research below: “The 'not reached' median OS in the experimental arm limits precise estimation of survival benefit magnitude.”